ARTICLE | Company News
Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630.
Revolution will receive an upfront payment of $50 million and is eligible for more than $500 million in development and regulatory milestones, plus tiered royalties up to mid-double digits in ex-U.S. markets...
BCIQ Target Profiles
Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11)